Levels of Target Activation Predict Antifibrotic Responses to Tyrosine Kinase Inhibitors

Annals of the Rheumatic Diseases - United Kingdom
doi 10.1136/annrheumdis-2013-203729
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Hitting the Target: Measuring EGFR Response to Tyrosine Kinase Inhibitors

Cancer Biology and Therapy
Cancer ResearchOncologyMolecular MedicinePharmacology
2005English

Progress in the Research of Multi-Target Tyrosine Kinase Inhibitors

Hans Journal of Medicinal Chemistry
2016English

Personalized Therapy of Tyrosine Kinase Inhibitors

Japanese Journal of Clinical Pharmacology and Therapeutics
Pharmacology
2013English

Tyrosine Kinase Inhibitors for Diabetes

Science-Business eXchange
2008English

Tyrosine Kinase Inhibitors in Lung Cancer

Hematology/Oncology Clinics of North America
OncologyHematology
2012English

Resistance to ErbB2 Tyrosine Kinase Inhibitors in Breast Cancer Is Mediated by Calcium-Dependent Activation of RelA

Molecular Cancer Therapeutics
Cancer ResearchOncology
2010English

Small Molecule FLT3 Tyrosine Kinase Inhibitors

2012English

Tyrosine Kinase Inhibitor and Target Therapy

2013English

Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy